Director, Platform Biology And Bioanalysis
CurrentGroup leader at CytomX Therapeutics, an innovative, clinical stage-oncology company developing Probody Therapeutics, which leverage the differential activity of the tumor microenvironment for improved efficacy and safety. I support platform development and innovation across all programs, including research alliances with Amgen, Astellas Pharma, Bristol Myers Squibb, Moderna, and Regeneron, as well as preclinical and clinical bioanalysis.